Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Current Immunotherapy Practices in Melanoma.

Rothermel LD, Sarnaik AA, Khushalani NI, Sondak VK.

Surg Oncol Clin N Am. 2019 Jul;28(3):403-418. doi: 10.1016/j.soc.2019.02.001. Epub 2019 Apr 12. Review.

PMID:
31079796
2.

Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes.

Miura JT, Dossett LA, Thapa R, Kim Y, Potdar A, Daou H, Sun J, Sarnaik AA, Zager JS.

Ann Surg Oncol. 2019 Apr 4. doi: 10.1245/s10434-019-07333-8. [Epub ahead of print]

PMID:
30949862
3.

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.

Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI.

Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14.

PMID:
30765391
4.

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.

Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA, Lowe M, Sarnaik AA, Zager JS, Ollila DW.

J Am Coll Surg. 2019 Apr;228(4):644-649. doi: 10.1016/j.jamcollsurg.2018.12.027. Epub 2019 Jan 25.

PMID:
30690076
5.

PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M.

Mol Cancer Res. 2019 Feb;17(2):583-593. doi: 10.1158/1541-7786.MCR-18-0777. Epub 2018 Oct 24.

PMID:
30355677
6.

Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?

Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS.

Ann Surg Oncol. 2019 Feb;26(2):379-385. doi: 10.1245/s10434-018-6810-1. Epub 2018 Oct 11.

PMID:
30311164
7.

Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.

Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, Sarnaik AA, Zager JS.

Ann Surg Oncol. 2018 Dec;25(13):3960-3965. doi: 10.1245/s10434-018-6803-0. Epub 2018 Oct 8.

PMID:
30298318
8.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

9.

Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?

Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS.

Ann Surg Oncol. 2018 Oct;25(11):3334-3340. doi: 10.1245/s10434-018-6688-y. Epub 2018 Aug 2.

PMID:
30073600
10.

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.

Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2018 Apr 25;13(4):e0196033. doi: 10.1371/journal.pone.0196033. eCollection 2018.

11.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA.

Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.

12.

Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions.

Glazer ES, Porubsky CF, Francis JD, Ibanez J, Castner N, Messina JL, Sarnaik AA, Harrington MA, Cruse CW, Sondak VK, Zager JS.

Ann Plast Surg. 2017 Jun;78(6):663-667. doi: 10.1097/SAP.0000000000000949.

13.

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.

Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA.

J Immunother Cancer. 2016 Oct 18;4:61. doi: 10.1186/s40425-016-0164-7. eCollection 2016.

14.

Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.

Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S.

Oncotarget. 2016 Jun 21;7(25):37893-37905. doi: 10.18632/oncotarget.9247.

15.

Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma.

Sarnaik AA, Zager JS, Sondak VK.

Oncology (Williston Park). 2016 Oct 15;30(10):891-2, 895. No abstract available.

16.

Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies.

Doepker MP, Yamamoto M, Applebaum MA, Patel NU, Jaime Montilla-Soler M, Sarnaik AA, Wayne Cruse C, Sondak VK, Zager JS.

Ann Surg Oncol. 2017 Feb;24(2):355-361. doi: 10.1245/s10434-016-5590-8. Epub 2016 Sep 22.

17.

High Frequency Jet Ventilation in Respiratory Failure Secondary to Respiratory Syncytial Virus Infection: A Case Series.

Valentine KM, Sarnaik AA, Sandhu HS, Sarnaik AP.

Front Pediatr. 2016 Aug 30;4:92. doi: 10.3389/fped.2016.00092. eCollection 2016.

18.

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.

Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2016 Apr 6;11(4):e0153053. doi: 10.1371/journal.pone.0153053. eCollection 2016.

19.

Developments in Intralesional Therapy for Metastatic Melanoma.

Sloot S, Rashid OM, Sarnaik AA, Zager JS.

Cancer Control. 2016 Jan;23(1):12-20. Review.

20.

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.

Sung H, Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, Yang S, Sarnaik AA, Sondak VK, Mulé JJ, Wilson RK, Weber JS, Kim M.

Oncotarget. 2016 Apr 26;7(17):23885-96. doi: 10.18632/oncotarget.8127.

21.

Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?

Doepker MP, Thompson ZJ, Fisher KJ, Yamamoto M, Nethers KW, Harb JN, Applebaum MA, Gonzalez RJ, Sarnaik AA, Messina JL, Sondak VK, Zager JS.

Ann Surg Oncol. 2016 Jul;23(7):2336-42. doi: 10.1245/s10434-016-5167-6. Epub 2016 Mar 8.

22.

Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy.

Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS.

J Am Coll Surg. 2016 Apr;222(4):702-9. doi: 10.1016/j.jamcollsurg.2015.12.033. Epub 2016 Jan 14.

23.

Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy.

Doepker MP, Thompson ZJ, Harb JN, Messina JL, Puleo CA, Egan KM, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS.

J Surg Oncol. 2016 Jan;113(1):98-102. doi: 10.1002/jso.24088. Epub 2015 Dec 10.

24.

Neonatal and Pediatric Organ Donation: Ethical Perspectives and Implications for Policy.

Sarnaik AA.

Front Pediatr. 2015 Nov 17;3:100. doi: 10.3389/fped.2015.00100. eCollection 2015. Review.

25.

Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties.

Chacon JA, Sarnaik AA, Pilon-Thomas S, Radvanyi L.

Oncoimmunology. 2015 Jul 1;4(12):e1040219. eCollection 2015 Dec.

26.

Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS.

Cancer. 2015 Sep 15;121(18):3252-60. doi: 10.1002/cncr.29452. Epub 2015 Jun 2.

27.

Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

Han D, Han G, Zhao X, Rao NG, Messina JL, Marzban SS, Sarnaik AA, Cruse CW, Sondak VK, Zager JS.

PLoS One. 2015 Mar 26;10(3):e0119716. doi: 10.1371/journal.pone.0119716. eCollection 2015.

28.

Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.

Yamamoto M, Fisher KJ, Wong JY, Koscso JM, Konstantinovic MA, Govsyeyev N, Messina JL, Sarnaik AA, Cruse CW, Gonzalez RJ, Sondak VK, Zager JS.

Cancer. 2015 May 15;121(10):1628-36. doi: 10.1002/cncr.29239. Epub 2015 Feb 11.

29.

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L.

Clin Cancer Res. 2015 Feb 1;21(3):611-21. doi: 10.1158/1078-0432.CCR-14-1934. Epub 2014 Dec 3.

30.

STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion.

Sun J, Lu F, He H, Shen J, Messina J, Mathew R, Wang D, Sarnaik AA, Chang WC, Kim M, Cheng H, Yang S.

J Cell Biol. 2014 Nov 24;207(4):535-48. doi: 10.1083/jcb.201407082. Epub 2014 Nov 17.

31.

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG.

Oncoimmunology. 2013 Sep 1;2(9):e25581. Epub 2013 Jul 3.

32.

Bronchoscopy with N-acetylcysteine lavage in severe respiratory failure from pertussis infection.

Mata AF, Sarnaik AA.

Pediatrics. 2013 Nov;132(5):e1418-23. doi: 10.1542/peds.2013-0912. Epub 2013 Oct 28.

PMID:
24167177
33.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.

J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi: 10.1200/JCO.2013.51.4802. Epub 2013 Oct 21.

34.

Recent advances in the treatment of melanoma.

Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR.

Cancer Control. 2013 Oct;20(4):244-5. No abstract available.

PMID:
24077400
35.

Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.

Cousar JL, Conley YP, Willyerd FA, Sarnaik AA, Puccio AM, Empey PE, Kochanek PM, Bell MJ, Okonkwo DO, Clark RS.

Neurocrit Care. 2013 Oct;19(2):192-8. doi: 10.1007/s12028-013-9881-7.

36.

Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2013 Jul 17;8(7):e68561. doi: 10.1371/journal.pone.0068561. Print 2013.

37.

Views of pediatric intensive care physicians on the ethics of organ donation after cardiac death.

Sarnaik AA, Clark JA, Meert KL, Sarnaik AP.

Crit Care Med. 2013 Jul;41(7):1733-44. doi: 10.1097/CCM.0b013e31828a219e.

PMID:
23660732
38.

Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects.

Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS.

Am Surg. 2013 May;79(5):476-82.

39.

Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.

Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S.

Cancer Immunol Immunother. 2013 Jun;62(6):1083-91. doi: 10.1007/s00262-013-1407-9. Epub 2013 Apr 19.

40.

Immunotherapy for gastrointestinal malignancies.

Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA.

Cancer Control. 2013 Jan;20(1):32-42. Review.

41.

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S.

J Immunol. 2012 Dec 1;189(11):5147-54. doi: 10.4049/jimmunol.1200274. Epub 2012 Oct 24.

42.

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA.

J Immunother. 2012 Oct;35(8):615-20.

43.

The unique clinical characteristics of melanoma diagnosed in children.

Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK.

Ann Surg Oncol. 2012 Nov;19(12):3888-95. doi: 10.1245/s10434-012-2554-5. Epub 2012 Aug 3.

44.

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS.

J Transl Med. 2012 Jul 12;10:146. doi: 10.1186/1479-5876-10-146.

45.

Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.

Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Cruse CW, Sarnaik AA, Puleo C, Sondak VK, Zager JS.

Ann Surg Oncol. 2012 Oct;19(11):3335-42. doi: 10.1245/s10434-012-2469-1. Epub 2012 Jul 6.

46.

Noninvasive ventilation in pediatric status asthmaticus: sound physiologic rationale but is it really safe, effective, and cost-efficient?

Sarnaik AA, Sarnaik AP.

Pediatr Crit Care Med. 2012 Jul;13(4):484-5. doi: 10.1097/PCC.0b013e31823db1ff. No abstract available.

PMID:
22766544
47.

Vulnerability to pediatric sepsis: all in the genes?.

Sarnaik AA.

Pediatr Crit Care Med. 2012 Mar;13(2):230-2. doi: 10.1097/PCC.0b013e3182191de9. No abstract available.

PMID:
22391838
48.

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.

Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20.

49.

Minimizing morbidity while preserving outcome after inguinal lymphadenectomy: navigating between scylla and charybdis.

Sondak VK, Sarnaik AA.

Ann Surg Oncol. 2011 Apr;18(4):909-11. doi: 10.1245/s10434-011-1549-y. No abstract available.

PMID:
21246401
50.

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.

Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS.

Clin Cancer Res. 2011 Feb 15;17(4):896-906. doi: 10.1158/1078-0432.CCR-10-2463. Epub 2010 Nov 24.

Supplemental Content

Loading ...
Support Center